Published 2025-01-01
“…Chongtu Yang,1,2,* Yidi Chen,1,2,* Liuji Sheng,1,2 Yanshu Wang,1,2 Xiaoyun Zhang,3 Yang Yang,4 Maxime Ronot,5 Hanyu Jiang,1,2 Bin Song1,2,6 1Department of Radiology, West China Hospital,
Sichuan University, Chengdu, People’s Republic of China; 2Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital,
Sichuan University, Chengdu, Sichuan, People’s Republic of China; 3Division of Liver Surgery, Department of General Surgery, West China Hospital,
Sichuan University, Chengdu, People’s Republic of China; 4Cancer Center, West China Hospital,
Sichuan University, Chengdu, Sichuan, People’s Republic of China; 5Department of Radiology, Hôpital Beaujon (Université de Paris), Clichy, France; 6Department of Radiology, Sanya People’s Hospital, Sanya, Hainan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Hanyu Jiang; Bin Song, West China Hospital,
Sichuan University, Chengdu, Sichuan, 610041, People’s Republic of China, Email hanyu_jiang@foxmail.com; songlab_radiology@163.comBackground: The combination of locoregional and systemic therapy may achieve remarkable tumor response for unresectable hepatocellular carcinoma (HCC).Objective: We aimed to investigate the correlation between radiologic and pathologic responses following combination therapy, evaluate their prognostic values, and to establish a non-invasive prediction system for pathologic response.Methods: This single-center retrospective study included 112 consecutive patients with HCC who underwent locoregional and systemic combination therapy followed by liver resection or transplantation. …”
Get full text
Article
